The effect of glucagon-like peptide 1 on cardiovascular risk

被引：0
|
作者：
Jacob Sivertsen
Jaya Rosenmeier
Jens J. Holst
Tina Vilsbøll
机构：
[1] Gentofte Hospital,Department of Cardiology
[2] University of Copenhagen,Diabetes Research Division, Department of Internal Medicine
[3] Gentofte Hospital,Department of Biomedical Sciences
[4] University of Copenhagen,undefined
[5] The NovoNordisk Foundation Center for Basic Metabolic Research,undefined
[6] The Panum Institute,undefined
[7] University of Copenhagen,undefined
来源：
Nature Reviews Cardiology | 2012年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Glucagon-like peptide 1 (GLP)-based therapies reduce blood glucose levels in patients with type 2 diabetes mellitus. Interestingly, GLP 1 receptor agonists can also have beneficial effects on cardiovascular risk. Dr. Sivertsen and colleagues provide an overview of the cardiovascular mechanisms targeted by GLP 1-based therapies and discuss clinical data for long-term management of cardiovascular risk in patients treated with these agents.
引用
收藏
页码：209 / 222
页数：13
相关论文
共 50 条
  • [31] Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1
    Ayahisa Watanabe
    Ken-ichi Nishijima
    Songji Zhao
    Yoshikazu Tanaka
    Takeshi Itoh
    Hiroshi Takemoto
    Nagara Tamaki
    Yuji Kuge
    Annals of Nuclear Medicine, 2012, 26 : 184 - 191
  • [32] Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective
    Fisher, M.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04): : 335 - 342
  • [33] Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1
    Furness, S. G. B.
    Christopoulos, A.
    Sexton, P. M.
    Wootten, D.
    BIOCHEMICAL PHARMACOLOGY, 2018, 156 : 223 - 240
  • [34] Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
    Marquis-Gravel, Guillaume
    Tardif, Jean-Claude
    DIABETES CARE, 2021, 44 (06) : 1252 - 1253
  • [35] Glucagon-like peptide-1 receptor agonists and aspiration risk
    McIsaac, Daniel I.
    Bryson, Gregory L.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 387
  • [36] Reframing the role of glucagon-like peptide 1 receptor agonists in cardiovascular medicine
    Inciardi, Riccardo M.
    Chandra, Alvin
    Pandey, Ambarish
    Metra, Marco
    ESC HEART FAILURE, 2025, 12 (02): : 923 - 926
  • [37] Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
    Ussher, John R.
    Drucker, Daniel J.
    NATURE REVIEWS CARDIOLOGY, 2023, 20 (07) : 463 - 474
  • [38] Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
    John R. Ussher
    Daniel J. Drucker
    Nature Reviews Cardiology, 2023, 20 : 463 - 474
  • [39] Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
    Chilton, Robert J.
    JOURNAL OF DIABETES & METABOLISM, 2015, 6 (01)
  • [40] Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
    Saraiva, Francisco Kerr
    Sposito, Andrei C.
    CARDIOVASCULAR DIABETOLOGY, 2014, 13
12345